Skip to main
  1. Stocks
  2. Aytu BioScience
  3. Forecast
AYTU

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma is supported by a stronger-than-expected fiscal Q4 FY26 performance, with revenue of $16.1 million rising 6% year over year and pro forma EPS of $0.03, both ahead of estimates. Its bullish case is anchored by EXXUA, which launched in Q4 2025 and has been described as highly encouraging, while its differentiated profile avoids labeled warnings for sexual dysfunction or weight gain and has shown symptom improvement in trials of more than 5,000 patients. With EXXUA targeting the $22 billion U.S. prescription MDD market, the company has substantial upside if commercialization scales, and even conservative FY27/FY28 expectations point to meaningful revenue growth and a path to profitability.

Bears say

Aytu BioPharma is exposed to a wide range of fundamental risks that could impair execution, including balance sheet and liquidity pressure, commercialization setbacks, and adverse shifts in investor sentiment toward biotech stocks. Its prospects also depend on successfully proving safety and efficacy in clinical trials and after FDA/postmarket approval, while maintaining regulatory approvals, securing reimbursement, and sustaining physician and patient adoption in a competitive market. Given its reliance on a single operating segment and a revenue mix concentrated in the ADHD Portfolio, any weakness in product performance, macroeconomic conditions, or healthcare priority shifts could disproportionately hurt results.

Aytu BioScience (AYTU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Aytu BioScience (AYTU) Analyst Forecast & Price Prediction

Get the latest Aytu BioScience (AYTU) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aytu BioScience (AYTU)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Aytu BioScience (AYTU) Analyst Forecast & Price Prediction

Get the latest Aytu BioScience (AYTU) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aytu BioScience (AYTU)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AYTU stock data and trends